You are here:  Home page > Research & Development


Zhejiang Medicine Co., Ltd.
168 Mid Zhiyuan Avenue,Binhai New Area,Shaoxing City,Zhejiang Province,312366, P.R.China

Tel: 0086-575-85211979

General situation of research & Development

Shaoxing Research Institute of Pharmaceutical Industry

The medical industry institute, one subordinate of the company, is the technological center of the state-level enterprise with the national postdoctoral scientific research station. The company sets up seven specialized institutes and has nearly two hundred researchers engaged in product research and development, technological innovation. The company invests more than CNY 100,000,000 to the research and development of new products every year.

Shanghai Laiyi Biological Medicine Research and Development Center

Shanghai Health Creation biological medicine research and development center was controlled by the company and jointly built by China Pharmaceutical University and Shanghai Jiaotong University, and its research field involves: new drug screening, activity research, new technology development, the development of non-patent drugs and the processing optimization and technical support of the export certification of the enterprise's products, etc.

The company is currently one of the domestic main production bases producing the resistant antibiotics, fluoroquinolone antibiotics, has a certain superiority over the research and development, production and market development of the resistant antibiotics, fluoroquinolone antibiotics, antimalarial drugs and diabetes drugs of glycosidase inhibitor class, immunosuppressant drugs and so on, and has strong international competitiveness.

The company has a state-level postdoctoral scientific research station and state-level enterprise technology center which has set up three original development and research platform of new drugs, respectively screening active material screening of endophyte, natural medicine active ingredients screening and "ME-BETTER" new drugs screening. Combining the advantage the known curative effect of our natural medicine, we found a lot of monomer substances of anti-tumor, antiviral, inhibit glycosidase with good activity in vivo and vitro.

In recent years, in order to further accelerate the pace of development and development of the new product, the company strengthened its cooperation with internationally renowned pharmaceutical companies and research institutions. In 2012, it signed the technology authorization and cooperation agreement with Taiwan Taijing Biological Technology Co., Ltd. and Taijing Biomedical Research and Development (Beijing) Co., Ltd. and obtained the exclusive patent license of the 1.1 class innovation medicine fluorine-free quinolone "nemonoxacin" within the territory of China. Its oral liquid is expected to be listed in 2014. In 2013, it signed the cooperative development and license agreement with American AMBRX, Inc. The two parties will work together to develop and commercialize a Her2-ADC product. The product uses a revolutionary technology of a new generation of single resistant coupling, which is mainly used for breast cancer indications.

By the end of 2015, we have cumulatively applied 490 domestic and international patents for invention, and 216 of them authorized.